Form 4: Voyager Therapeutics Executive Todd Alfred Carter Reports Stock Transactions

Chief Scientific Officer Todd Alfred Carter reports the sale of shares to cover tax obligations and the acquisition of restricted stock units and stock options in Voyager Therapeutics.

Summary

• Todd Alfred Carter, Chief Scientific Officer of Voyager Therapeutics, reported transactions involving the company's stock.
• On February 20, 2025, Carter sold 3,305 shares of common stock at a weighted average price of $4.26 to cover tax obligations related to vesting restricted stock units.
• The shares were sold in multiple transactions with prices ranging from $4.21 to $4.39.
• On February 21, 2025, Carter acquired 46,000 shares of common stock through restricted stock units (RSUs) and was granted options to purchase 92,000 shares.
• Following these transactions, Carter beneficially owns 123,718 shares of Voyager Therapeutics common stock and options to purchase 92,000 shares.
• The RSUs vest over three years, and the stock options vest over four years, subject to continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations. There's no indication of unusual or concerning activity.

Positives

• The grant of RSUs and stock options to a key executive like the Chief Scientific Officer can be seen as an incentive to align their interests with the long-term success of the company.
• The vesting schedules for the RSUs and options (three and four years, respectively) encourage continued service and commitment from the executive.

Future Outlook

The vesting schedules of the RSUs and stock options indicate a multi-year commitment from the executive.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• The vesting of RSUs and stock options aligns the executive's interests with those of shareholders.

Key Dates

Keywords

Voyager Therapeutics, Todd Alfred Carter, stock options, restricted stock units, Form 4, beneficial ownership, insider trading, VYGR